Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

In this study of 4758 HIV-1–serodiscordant heterosexual couples in Kenya and Uganda, daily antiretroviral prophylaxis (with tenofovir or emtricitabine–tenofovir) in the HIV-1–negative partner significantly decreased the risk of HIV infection. The use of antiretroviral medications for the prevention...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 367; no. 5; pp. 399 - 410
Main Authors: Baeten, Jared M, Donnell, Deborah, Ndase, Patrick, Mugo, Nelly R, Campbell, James D, Wangisi, Jonathan, Tappero, Jordan W, Bukusi, Elizabeth A, Cohen, Craig R, Katabira, Elly, Ronald, Allan, Tumwesigye, Elioda, Were, Edwin, Fife, Kenneth H, Kiarie, James, Farquhar, Carey, John-Stewart, Grace, Kakia, Aloysious, Odoyo, Josephine, Mucunguzi, Akasiima, Nakku-Joloba, Edith, Twesigye, Rogers, Ngure, Kenneth, Apaka, Cosmas, Tamooh, Harrison, Gabona, Fridah, Mujugira, Andrew, Panteleeff, Dana, Thomas, Katherine K, Kidoguchi, Lara, Krows, Meighan, Revall, Jennifer, Morrison, Susan, Haugen, Harald, Emmanuel-Ogier, Mira, Ondrejcek, Lisa, Coombs, Robert W, Frenkel, Lisa, Hendrix, Craig, Bumpus, Namandjé N, Bangsberg, David, Haberer, Jessica E, Stevens, Wendy S, Lingappa, Jairam R, Celum, Connie
Format: Journal Article
Language:English
Published: Waltham, MA Massachusetts Medical Society 02-08-2012
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study of 4758 HIV-1–serodiscordant heterosexual couples in Kenya and Uganda, daily antiretroviral prophylaxis (with tenofovir or emtricitabine–tenofovir) in the HIV-1–negative partner significantly decreased the risk of HIV infection. The use of antiretroviral medications for the prevention of HIV type 1 (HIV-1) transmission is a promising strategy for reducing the spread of HIV-1. 1 – 4 Antiretroviral treatment for persons infected with HIV-1 provides important clinical benefits and substantially reduces infectiousness. 5 – 7 Antiretroviral prophylaxis is a potential HIV-1–prevention strategy for those not yet infected with HIV-1, administered either as postexposure prophylaxis after high-risk occupational or nonoccupational exposure or as preexposure prophylaxis in those with ongoing HIV-1 exposure. 8 , 9 The rationale for antiretroviral prophylaxis in persons with ongoing exposure is based on its efficacy in infants exposed to HIV-1 during birth and . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1108524